Last reviewed · How we verify

NCT03877497: TRUST

To Reach Unrestricted Services for Transgender Women

Completed NA Last updated 10 December 2024
What this trial tests

NA trial testing Adapted SBIRT-T for transgender women in Transgender Women in 86 participants. Completed in 4 December 2024.

Timeline
19 September 2019
Primary endpoint
31 May 2024
4 December 2024

Quick facts

Lead sponsorUniversity of Central Florida
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment86
Start date19 September 2019
Primary completion31 May 2024
Estimated completion4 December 2024
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Central Florida

Who can join

18 and older, male only, with Transgender Women or Substance Abuse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Florida has the fifth largest transgender population in the United States. Transgender women, particularly those of color, in the southern part of Florida are a marginalized population who are impacted by co-morbidities of substance abuse and HIV in their communities. The overall objective of the study is to use a vetted adapted brief intervention to stem the development of substance abuse in at-risk transgender women, and thereby increase primary and secondary prevention methods such as routine HIV screening, uptake of pre-exposure prophylaxis (PrEP) and use of non-occupational post-exposure prophylaxis (nPEP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Central Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing